- Details
- Ashish Kamat introduces Stephen B. Williams who discusses findings from his study on blue light cystoscopy in bladder cancer treatment, conducted within the VA healthcare system. The study utilized a propensity score-matched analysis to compare the outcomes of blue light versus white light cystoscopy, focusing on bladder cancer recurrence, progression, and overall survival. The analysis revealed s...
|
- Details
- Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance applications, emphasizing selective utilization and benefits post-BCG therapy. Dr. Williams references a study in Clinical Genitourinary Cancer, sharing insights from a study comparing blue and white...
|
- Details
- Tamer Aboushwareb, Vice President of Medical Affairs, Pacific Edge, Ltd provides an overview of the Cxbladder Monitor urine-based cancer surveillance test and is joined by Neal Shore and Josh Meeks for a discussion on the clinical implications of the use of this test. Several supportive publications are highlighted and Drs Shore, Meeks, and Aboushwareb discuss the Cxbladder Monitor algorithm, its...
|
- Details
- Neal Shore joins Alicia Morgans to discuss the benefits of Blue light cystoscopy (BLC) when patients receive this option for bladder cancer care in ambulatory surgery centers. BLC enhances urologists' ability to detect cancerous tissue, leading to more complete resection and reduced costs for the US healthcare system. Reimbursement for outpatient ambulatory surgery centers or clinics could be more...
|
- Details
- Ashish Kamat welcomes Siamak (Sia) Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy. He highlights the study's analysis of detection sensitivity across different races, revealing that while blue light enhances tumo...
|
- Details
- Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection in China. Conducted across seven hospitals from November 2022 to June 2023, the study involved 158 patients, with 114 remaining in the final analysis. It demonstrates that BLC, especially with Hexaminolevulinate (HAL) and modern 4K L...
|
- Details
- Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent, interacting with the heme biosynthetic pathway, causes cancer cells to accumulate photo porphyrins that light up under specific wavelengths. This technology is crucial for patients suspected of having or with a history of bladder cancer, enhan...
|
- Details
- Zach Klaassen hosts Mark Tyson for a discussion on the noninvasive urinary genomic biomarker test, Cxbladder. Dr. Tyson explains that Cxbladder Detect assesses bladder cancer risk in patients with microscopic hematuria by analyzing urine for specific mRNA biomarkers. The test aims to reduce invasive diagnostics like cystoscopy, aligning with AUA guidelines for a risk-stratified approach. Their dec...
|
- Details
- Stephen Williams joins Ashish Kamat presenting findings on macro and microeconomics of blue light cystoscopy (BLC) with CYSVIEW® in the care of patients with non-muscle invasive bladder cancer, a Urologic Oncology Seminars and Original Investigations publication. The aim of the study was to determine the estimated budget impact to practices that incorporate blue light cystoscopy with hexaminolevul...
|
- Details
- Zach Klaassen is joined by Karsten Zieger to talk about the results of an analysis from the Nordic registry evaluating the role of flexible blue light cystoscopy in the surveillance of non-muscle invasive bladder cancer. Dr. Zieger provides a comprehensive explanation of how blue light cystoscopy works. The method utilizes a photosensitizing agent, Hexvix in Europe or Cysview® in the U.S., that al...
|
